Desitin, Pozen sales and marketing update

Desitin received exclusive rights to develop and commercialize Pozen's migraine drug MT 400 in the EU, Switzerland and Norway. Pozen will receive $500,000 up front and is eligible for $2.5 million in pre-commercialization milestones, plus double-digit royalties that will increase based on annual sales volume. ...